Nevin KARAKUŞ, Serbülent YİĞİT, İsmail OKAN, Nurten KARA

Evaluation of BRCA1 and BRCA2 gene mutations in breast cancer patients

Amaç: Dünya çapında, meme kanseri kadınlarda en sık görülen kanserdir. Türkiye'de de meme kanseri tüm kadın kanserlerinin %25'i gibi bir sıklıkta kadınlarda en sık görülen kanserdir. Tümör baskılayıcı genlerdeki (BRCA1 ve BRCA2) germline mutasyonlar kanser için genetik yatkınlığa neden olur ve tüm meme ve yumurtalık kanserlerinin %510'undan sorumludur. BRCA1 veya BRCA2 genlerinde mutasyon taşıyan kadınlar, özellikle 45 yaşından önce meme kanserine yakalanmak için yüksek riske sahiptir. Bu çalışmanın amacı, en yaygın olan BRCA1 ve BRCA2 gen mutasyonlarının, Türk populasyonunda erken yaş meme kanserli hastalardaki sıklığını belirlemektir. Yöntem: Bu çalışmaya, erken yaş (

Meme kanserli hastalarda BRCA1 ve BRCA2 gen mutasyonlarının değerlendirilmesi

Objective: Worldwide, breast cancer is the most common malignancy among women. In Turkey, breast cancer is also the most common cancer among women with the frequency of 25% of all female cancers. Germline mutations in tumor suppressor genes (BRCA1 and BRCA2) cause genetic susceptibility to malignancies and are responsible for 5-10% of all breast and ovarian cancers. Women carrying mutations in BRCA1 or BRCA2 genes are at high risk to develop breast cancer, especially before the age of 45. The aim of this study was to determine the frequencies of the most common BRCA1 and BRCA2 gene mutations (185delAG and 5382insC in BRCA1 gene and 6174delT in BRCA2) in patients with early-onset breast cancer in a Turkish population. Method: 50 female early-onset (

PDF

___

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61: 69-90.
Turkish Ministry of Health: Turkish Public Health Institution, Turkey Cancer Statistics, Ankara, 2016.
Fredslund SO, Bonefeld-Jorgensen EC. Breast cancer in the Arctic-changes over the past decades. Int J Circumpolar Health 2012; 71: 19155.
Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998; 16: 1969-77.
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer
Raieevi L. Breast cancer susceptibility Gene 2 - BRCA2. Archive of Oncology 2001; 9: 115- 8.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-90.
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfellow M, Stroup C, Swedlund B, Swense J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AK, Shizuya H, Eyfjord JE, Cannon-Albright L, Tranchant M, Labrie F, Skolnick MH, Weber B, Kamb A, Goldgar DE. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature Genet 1996; 12: 333-7.
Wang B, Hurov K, Hofmann K, Elledge SJ. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev 2009; 23: 729- 39.
Phelan CM, Kwan E, Jack E, Li S, Morgan C, Aubé J, Hanna D, Narod SA. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum Mutat 2002; 20: 352-7.
Karakus N, Kara N, Ulusoy AN, Ozaslan C, Tural S, Okan I. Evaluation of CYP17A1 and LEP Gene Polymorphisms in Breast Cancer. Oncol Res Treat 2015; 38: 418-22.
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AM, Hogervorst F, Brohet R, Ligtenberg MJ, Teugels E, van der Luijt R, van der Hout AH, Gille JJ, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJ, Bakker MM, Devilee P, et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 1997; 60: 1041-9.
Yazici H, Bitisik O, Akisik E, Cabioglu N, Saip P, Muslumanoglu M, Glendon G, Bengisu E, Ozbilen S, Dincer M, Turkmen S, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients. Br J Cancer 2000; 83: 737-42.
Sokolenko AP, Mitiushkina NV, Buslov KG, Bit-Sava EM, Iyevleva AG, Chekmariova EV, Kuligina ESh, Ulibina YM, Rozanov ME, Suspitsin EN, Matsko DE, Chagunava OL, Trofimov DY, Devilee P, Cornelisse C, Togo AV, Semiglazov VF, Imyanitov EN. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 2006; 42: 1380-4.
Balci A, Huusko P, Paakkonen K, Launonen V, Uner A, Ekmekci A, Winqvist R. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414 del4 found in male breast cancer. Eur J Cancer 1999; 35: 707-10.
Yazici H, Glendon G, Yazici H, Burnie SJ, Saip P, Buyru F, Bengisu E, Andrulis IL, Dalay N, Ozcelik H. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in nonfamilial cases. Hum Mutat 2002; 20: 28-34.
Egeli U, Cecener G, Tunca B and Tasdelen I. Novel germline BRCA1 and BRCA2 mutations in Turkish women with breast and/or ovarian cancer and their relatives. Cancer Invest 2006; 24: 484-91.
Aktas D, Gultekin M, Kabacam S, Alikasifoglu M, Turan AT, Tulunay G, Kose MF, Ortac F, Yüce K, Tunçbilek E, Ayhan A. Identification of point mutations and large rearrangements in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients. Gynecol Oncol 2010; 119: 131-5.
Purcu DU, Karaca B, Kapkac M, Ozdemir N, Uzunoglu S, Uslu R. High-Resolution Melting Analysis for Screening of Turkish Germline Mutations in BRCA1 and BRCA2 Int J Hematol Oncol 2010; 4: 235-40.
Manguoğlu E, Güran S, Yamaç D, Colak T, Simşek M, Baykara M, Akaydın M, Lüleci G. Germline mutations of BRCA1 and BRCA2 genes in Turkish breast, ovarian, and prostate cancer patients. Cancer Genet Cytogenet
Haytural H, Yalcinkaya N, Akan G, Arikan S, Ozkok E, Cakmakoglu B, Yaylim I, Aydin M, Atalar F. Identification of a novel BRCA2 and CHEK2 A-C-G-C haplotype in Turkish patients affected with breast cancer. Asian Pac J Cancer Prev 2013; 14: 3229-35.
Cecener G, Egeli U, Tunca B, Erturk E, Ak S, Gokgoz S, Tasdelen I, Tezcan G, Demirdogen E, Bayram N, Avci N, Evrensel T. BRCA1/2 Germline Mutations and Their Clinical Importance in Turkish Breast Cancer Patients. Cancer Invest 2014; 32: 375-87.
Backe J, Hofferbert S, Skawran B, Dörk T, Stuhrmann M, Karstens JH, Untch M, Meindl A, Burgemeister R, Chang-Claude J, Weber BH. Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 1999; 72: 402-6.
Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubinski J. Founder mutations in the BRCA1 gene in Polish families with breastovarian cancer. Am J Hum Genet 2000; 66: 1963-8.
Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MB, Florentin L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D. BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat 2000; 16: 272-3.
Machácková E, Foretová L, Navrátilová M, Valík D, Claes K, Messiaen L. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast- ovarian cancer families. Cas Lek Cesk 2000; 139: 635-7.
Tereschenko IV, Basham VM, Ponder BA, Pharoah PD. BRCA1 and BRCA2 mutations in Russian familial breast cancer. Hum Mutat 2002; 19: 184.
Guran S, Ozet A, Dede M, Gille JJP, Yenen MC. Hereditary breast cancer syndromes in a Turkish population: results of molecular germline analysis. Cancer Genet Cytogenet 2005; 160: 164-8.
Ozdag H, Tez M, Sayek I, Muslumanoglu M, Tarcan O, Icli F, Oztürk M, Ozçelik T. Germ line BRCA1 and BRCA2 gene mutations in Turkish breast cancer patients. Eur J Cancer 2000; 36: 2076-82.
Manguoglu AE, Luleci G, Ozcelik T, Colak T, Schayek H, Akaydin M, Friedman E. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003; 21: 444-5.
Aydin F, Akagun T, Yildiz B, Fidan E, Ozdemir F, Kavgaci H. Clinicopathologic characteristics and BRCA-1/BRCA-2 mutations of Turkish patients with breast cancer. Bratisl Lek Listy 2011; 112: 521-3.
Erturk E, Cecener G, Polatkan V, Gokgoz S, Egeli U, Tunca B, Tezcan G, Demirdogen E, Ak S, Tasdelen I. Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer. Asian Pac J Cancer Prev 2014; 15: 8319-24.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
Chappuis PO, Nethercot V, Foulkes W. Clinico-pathological characteristics of BRCA1- and BRCA2- related breast cancer. Semin Surg Oncol 2000; 18: 287-95.